In patients with secondary hypogonadism who wish to preserve fertility, alternatives to testosterone therapy, such as human chorionic gonadotropin (hCG), selective estrogen receptor modulators (SERMs), and aromatase inhibitors (AIs), are available, although these options remain off-label and lack robust efficacy data [14]. The gene discussed is CYP19A1; the disease is hypogonadotropic hypogonadism.